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STRUCTURED ABSTRACT 
Objectives: The anti-diabetic properties of metformin are mediated through its ability to activate 
the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumour formation 
and inhibit cell growth, in addition to lowering blood glucose levels. We tested the hypothesis 
that metformin reduces the risk of cancer in people with type 2 diabetes. Research Design and 
Methods: In an observational cohort study using record-linkage databases, based in Tayside, 
Scotland, UK, we identified people with type 2 diabetes who were new users of metformin in 
1994-2003. We also identified a set of diabetic comparators, individually matched to the 
metformin users by year of diabetes diagnosis, who had never used metformin. In a survival 
analysis we calculated hazard ratios for diagnosis of cancer, adjusted for baseline characteristics 
of the two groups using Cox regression. Results: Cancer was diagnosed among 7.3% of 4,085 
metformin users compared with 11.6% of 4,085 comparators, with median times to cancer of 3.5 
years and 2.6 years respectively (p < 0.001). The unadjusted hazard ratio for cancer was 0.46 
(0.40–0.53). After adjusting for sex, age, BMI, HbA1c, deprivation, smoking and other drug use, 
there was still a significantly reduced risk of cancer associated with metformin: 0.63 (0.53–0.75). 
Conclusions: These results suggest that metformin use may be associated with a reduced risk of 
cancer. A randomized trial is needed to assess whether metformin is protective in a population at 
high risk for cancer.  
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Recent research suggests that the anti-diabetic drug metformin, which exerts its effects by 
activating the AMP-activated protein kinase (AMPK) may have potential for the treatment of 
cancer in humans
1
. The hypothesis that metformin may have anti-cancer effects is supported by 
laboratory studies, showing that metformin is associated with reduced incidence of pancreatic 
cancer in hamsters
2
, and delays onset of mammary
3
 and other tumours
4
 in tumour-prone mice. 
Metformin also inhibits growth of human breast cancer cells
5
. Although the potential for 
prevention of cancer in humans using metformin has not been explored, we previously reported 
the results of a pilot case-control study that identified a reduced risk of cancer among patients 
with type 2 diabetes who had used metformin
6
. However, the outcome was limited to hospital 
admissions for cancer, and the date of diagnosis was assumed to be date of first hospital 
admission.  
 
Other diabetic drugs may also have cancer-related effects. An independent epidemiological study 
found that users of sulphonylureas were at higher risk of cancer-related mortality than metformin 
users
7
.  Sulphonylureas (and insulin) increase circulating insulin levels and hyperinsulinaemia 
may promote carcinogenesis
8
. Treatments such as metformin and glitazones reduce insulin 
resistance, with insulin resistance possibly associated with increased risk of cancer
9. 
 The 
objective of this study was to test the hypothesis that metformin use is associated with a reduced 
risk of cancer in people with type 2 diabetes, using a national cancer registry to ensure valid 
diagnoses of cancer, with precise dates of diagnosis. We also adjusted results for the effects of 
exposure to other diabetic drugs.  
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RESEARCH DESIGN AND METHODS 
Data Sources 
This observational, historical cohort study was carried out using anonymous patient data for the 
resident population of Tayside Health Board in Scotland, UK (approx. 400,000 people). Data 
were provided by the Health Informatics Centre (HIC), University of Dundee, which has 
developed the record-linkage of multiple, routinely collected data sets for research. SCI-DC 
(formerly known as DARTS) is a validated population-based diabetes register with detailed 
clinical information
10
. A pharmacoepidemiological database (formerly known as the MEMO 
drug safety database) holds computerised records of every diabetic drug dispensed to Tayside 
residents since 1993
11
.  Scottish Morbidity Record 6 (SMR6) is a national database of all 
diagnoses of cancer
12
. Computerised death certification records from the Registrar General, with 
ICD9/ICD10-coded causes of death
13,14
, were also available. All HIC data are anonymised prior 
to analysis to maintain confidentiality and conform to data protection legislation.   
 
Study design  
The DARTS database was used to identify  patients who were diagnosed with type 2 diabetes in 
Tayside before 2004 (patients diagnosed over 35 years are classified as type 2 diabetes, as are 
younger patients with no insulin requirement).  
 
Metformin users 
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We identified patients who received a first metformin prescription any time between 1
st
 January 
1994 and December 2003 (excluding patients who received metformin in 1993 or before their 
diabetes diagnosis). We classified these patients as metformin users and defined their index date 
as date of first metformin prescription. Patients who had a record of cancer on SMR6 at any time 
between 1980 and their index date were excluded.   
 
Comparator cohort 
Comparator patients individually matched to the metformin users were generated at random from 
a pool of patients with type 2 diabetes who had no record of metformin use. We used a computer 
algorithm that identified comparators for each metformin user (listed in random order). For each 
metformin user, a potential comparator was identified with the same year of diagnosis and 
assigned the same index date. Year of diagnosis was chosen as a matching variable to control for 
effects of treatment patterns which could vary over time but not be measured directly. However, 
if there was a record of cancer on SMR6 prior to the index date, or if they had died, the 
comparator was discarded (but was potentially available for a different metformin user). This 
process was repeated until suitable comparators were identified. The comparators that were 
identified for metformin users were therefore diagnosed with diabetes in the same year, and 
survived until the index date without cancer (the date that their corresponding metformin user 
started metformin). Any potential survival bias (meformin users surviving to go on to metformin) 
was thus eliminated. 
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Baseline data were collated for all metformin users and comparators: age at index date, age at 
diagnosis of diabetes, sex, smoking status, mean body mass index (BMI) and HbA1c during the 
study period, use of sulphonylureas or insulin within 3 months or 1 year of the index date 
respectively. An area-based measure of material deprivation (Carstairs score
15
) based on four 
variables from the national census (car ownership, unemployment, overcrowding and head of 
household job classification) was also used.  
 
Main outcome measures 
We followed up all patients from their index dates for pre-defined outcomes. The primary 
outcome was diagnosis of cancer (as recorded on SMR6). Time to outcome was defined as the 
period from index date to (a) date of diagnosis of cancer on SMR6 (b) date of death if no cancer 
diagnosis (c) end of the study (31
st
 December 2003) if no cancer diagnosis.  
 
Secondary outcomes 
We evaluated the risks of the following secondary outcomes: diagnosis with bowel cancer (ICD9 
153-154, ICD10 C18-C20), lung cancer (ICD9 162, ICD10 C33-C34) or breast cancer in women 
(ICD9 174, ICD10 C50), all-cause mortality and mortality from cancer (any mention on death 
certificate).  
 
Statistical methods 
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Time from index date to outcome in the cohorts was shown using Kaplan Meier plots. The 
proportional hazards assumption was examined using log (-log) survival plots, parallel lines 
indicating that the assumption was reasonable. The relationship between metformin use and 
diagnosis of cancer was assessed in a Cox regression unadjusted, and then in a multivariable 
model adjusted for age at index date, sex, smoking status, deprivation, mean body mass index 
(BMI) and HbA1c during the study period, and use of sulphonylureas and insulin. These were all 
treated as categorical variables (as defined in Table 1), with the exception of HbA1c and BMI 
which were treated as continuous variables. The analyses were stratified by year of diagnosis 
(the matching variable).  
 
Dose-response analyses 
For each metformin user, we identified the maximum metformin dose prescribed during follow-
up. We then categorised these as low dose (less than 50% of maximum prescribable dose), 
medium dose (50-80% of maximum prescribable dose), and high dose (more than 80%). The 
risks associated with each dose level were determined in a stratified analysis, with adjustments 
for all covariates. However, in case of confounding by duration of follow-up, we further 
stratified patients according to length of time in the study.  
 
Ethical Approval 
Ethical approval was obtained from the Multi-Centre Research and Ethics Committee for 
Scotland. 
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Role of funding source 
The study was funded by Tenovus, Scotland. The researchers were independent. The funding 
source had no involvement in study design or analysis.  
 
RESULTS 
There were 13,344 patients alive in January 1993 who were diagnosed with type 2 diabetes in 
Tayside before 2004, of which 12,255 were eligible for the study. We identified 5,183 patients 
who received a first prescription for metformin after 1994, and selected 4,944 for whom there 
was no cancer diagnosis prior to metformin use. The remaining patients were 5,883 patients who 
received no metformin prescriptions between 1993 and 2004, and 1,189 who received a 
prescription for metformin in 1993. These latter patients were excluded as their date of starting 
metformin was unknown (no prescribing data available prior to 1993). Fig 1 shows how patients 
were selected for the study. 
 
Metformin users and comparators 
The computer algorithm was used to identify comparators for the 4,804 metformin users who 
were aged 35 years or over at their index date. The comparators were identified from the 5,773 
patients who were over 35 years and had no record of metformin use. A comparator was 
identified for 4,364 users (the remaining 440 metformin users for whom comparators could not 
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be found were excluded). However, all further analyses were restricted to the 4,085 metformin 
users who had more than one prescription for metformin, and their respective comparators.  
 
The baseline characteristics of the two groups are presented in Table 1. Metformin users were 
younger than their comparators and slightly more likely to be current smokers (although smoking 
status was unavailable for about a quarter of study subjects). BMI and HbA1c values were also 
unavailable for 3% and 9% of study subjects respectively, who were therefore assigned the mean 
values. Metformin users had higher mean values of BMI and HbA1c. There was a much higher 
proportion of metformin users who were treated with sulphonylureas within 3 months, but a 
lower proportion who used insulin within a year. These differences were all statistically 
significant.   
 
Main outcome measures 
Cancer was diagnosed among 297 (7.3%) of the metformin users during follow-up, compared 
with 474 (11.6%) of the comparators. Median time to cancer was 3.5 years (IQR 2.1 – 5.8 years) 
for metformin users, compared with 2.6 years (IQR 1.2 – 4.1 years) for comparators. Fig 2 shows 
the Kaplan-Meier plot for diagnosis of cancer (log rank test p < 0.001). The proportional hazards 
assumption was met for all study subjects. 
 
The unadjusted Cox regression showed a statistically significant reduction in the risk of cancer in 
the new metformin users with a hazard ratio of 0.46 (0.40 – 0.53) (Table 1). Increased cancer 
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risk was observed among males and with increasing age. It also appeared that higher BMI and 
HbA1c were associated with a reduced risk of cancer. This is difficult to explain, but may be a 
diagnostic bias, with high BMI and HbA1c indicative of less frequent health care seeking 
behaviour.  
 
In the multivariable analysis, the adjusted hazard ratio increased to 0.63 (0.53 - 0.75) for 
metformin use. Never and ex smokers were at reduced risk of cancer, but the reduced risks 
associated with increased BMI and HbA1c were less marked. No statistically significant effects 
were observed for use of sulphonyureas or insulin.  
 
Secondary outcomes 
The unadjusted and adjusted risks of the secondary outcomes are presented in Table 2. 
Metformin users were at much lower risk of overall mortality and cancer-related mortality than 
their comparators. Overall, 14.9% of metformin users died, compared with 34.8% of the 
comparators. The median survival times were 3.6 years (IQR 2.2 – 5.9 years) and 2.8 years (1.4 
– 4.3 years) respectively. 3.0% of metformin users died from cancer, compared with 6.1% of 
comparators. Reduced risks of a similar magnitude to that for all cancers were observed for 
bowel cancer, lung cancer and breast cancer, although the results were not all statistically 
significant.   
 
Dose-response analysis 
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The stratified analysis for maximum dose is also presented in Table 2. Although none of the risks 
for low, medium and high doses stratified by length of follow-up were significantly different 
from each other (as indicated by overlapping confidence intervals), there was a clear trend for 
metformin users to have a higher risk of cancer in the first two years of follow-up. However, 
after this, among patients with the same duration of follow-up, the risk appeared to be lower with 
the highest metformin doses.  
 
CONCLUSIONS 
This study supports the hypothesis that users of metformin are at lower risk of cancer compared 
with people with type 2 diabetes on other treatments. Fewer than 8% of a cohort of metformin 
users were diagnosed with cancer during a maximum of 10 years of follow-up, compared with 
11% of a comparator cohort of non-users. The median time to cancer was 3.6 years among 
metformin users, compared to 2.5 years among comparators, and they also had reduced overall 
and cancer-related mortality.  
 
This was an observational study therefore we could not control for all differences between study 
groups. Users of metformin could have been at lower baseline risk of cancer than the 
comparators. Indeed, they were younger than their comparators (but mean BMI and HbA1c were 
higher). Metformin users did seem to be a different group clinically from non users, with a much 
lower rate of mortality (some of which could be explained by their lower risk of cardiovascular 
mortality
16
). While this limitation is inherent in the observational nature of the study, we adjusted 
results for known potential confounders and there were sizable changes to the risk estimates. 
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There may still have been residual confounding, or unknown confounders, but it is unlikely that 
this could account for the entire 37% reduced risk of cancer observed.  
 
Adjusting for use of other diabetic drugs was necessary because there was a higher proportion of 
metformin users who were treated with sulphonylureas compared with the comparators, but a 
lower proportion treated with insulin. This probably reflects the heterogeneity of the pool of 
potential comparators. Patients not treated with metformin will encompass those who do not yet 
require oral therapy, and also those who have progressed to insulin after treatment with 
sulphonylureas only. However, we found no statistically significant independent effects of 
sulphonylureas and insulin on risk of cancer in the Cox regression analysis. In contrast, males 
and older people were at increased risk of cancer, as might be expected. The results were similar 
for specific cancer types.  
 
In a dose-response analysis, metformin users appeared to have a higher risk of cancer during the 
first two years of follow-up. This may be because patients who begin treatment with metformin 
are more likely to have cancer diagnosed as they have increasing contact with health care 
professionals. In later years of follow-up, high maximum doses of metformin were associated 
with the greatest reduction in risk of cancer.  Metformin dose usually increases with increasing 
duration of use, therefore dose variables can be confounded by duration. This could produce a 
survival bias, with higher doses spuriously associated with reduced cancer because patients have 
survived to receive a higher dose. This is the reason for stratification by length of follow-up 
(although residual confounding may still be present). 
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Within the known limitations of observational data, we are confident in our study design and 
data sources. The data sources used were independent of each other, and they provided objective 
measures of exposure and outcome.  The diabetic population of Tayside is well-defined, and the 
MEMO database used to identify metformin users has been widely used for drug safety 
research
11
. The likelihood of misclassification of metformin exposure due to data error is low 
because we ensured that all patients had multiple metformin prescriptions. We were otherwise 
unable to judge whether patients actually took the metformin as prescribed, although we know 
that the drug was collected from the pharmacies
11
. We are confident that we eliminated survival 
bias in our choice of comparators. The national cancer registry (SMR6) was used to identify 
cancer diagnoses. Specificity is likely to be higher than sensitivity in this register, but if any 
cancer diagnoses were missed, this would not occur differentially with respect to metformin 
status.  
 
This study has produced sufficient epidemiological evidence that metformin reduces the risk of 
cancer to make further investigation a high priority.  A plausible biological mechanism 
mechanism hinges on the discovery that the upstream LKB1 regulator of AMPK is a tumour 
suppressor, and that activation of AMPK by LKB1 plays an important role in inhibiting cell 
growth when cellular energy levels are low
17
. Metformin activates AMPK by inhibiting 
mitochondrial respiration and increasing 5’-AMP which enhance activation of AMPK by LKB11. 
The blood glucose lowering properties of metformin are mediated through AMPK restoring 
cellular energy levels by phosphorylating regulatory proteins that lead to stimulation of glucose 
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uptake into muscle tissues and inhibition of gluconeogenesis in the liver. The anti-cancer 
properties of metformin are likely to be mediated by AMPK ability to preserve cellular energy 
levels by phosphorylating proteins such as p27KIP and TSC2 that lead to inhibition of cell 
growth and proliferation signalling networks
18,19
.  
 
Prior to the discovery that the LKB1 tumour suppressor activated AMPK, there was little interest 
in the role of AMPK in cancer. However, the ability of AMPK to gauge and control cellular 
energy places it in an ideal position to ensure that cell growth and proliferation is coupled to the 
availability of a sufficient supply of nutrients and energy. Recent laboratory evidence showing 
that three distinct drugs activate AMPK delayed tumourigenesis in tumour prone mice, suggests 
that activators of AMPK could have therapeutic benefit for the treatment of cancer in humans
4
. 
The protective effects of metformin on cancer development could potentially be rapid, and may 
occur at quite a late stage of cancer development.  Treatment of animal cells with metformin 
significantly activates the AMPK pathway within 30 minutes
20-22
.  Metformin also inhibits 
growth of cancer cells
5
 or mouse embryonic stem cells
4
 within 1-2 days. We believe that there is 
now a strong case to conduct a randomized trial to establish whether metformin is protective in a 
population at high risk for cancer.  
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Table 1: Baseline characteristics and results of Cox regression analysis for incidence of cancer, among 
metformin users and comparators 
 Metformin 
users  
(n = 4,085) 
N (%) 
Comparato
rs 
(n = 4,085) 
N (%) 
No. of 
diagnosed 
cancers  
Unadjusted 
hazard ratio (95% 
CI) 
Adjusted hazard ratio
*
  
(95% CI) 
Metformin use      
Comparators  4,085 - 474 1.00 1.00 
Metformin  
users 
- 4,085 297 0.46 (0.40 – 0.53) 0.63 (0.53 – 0.75) 
Sex      
Females 1848 (45.9) 1875 (45.2) 315 1.00 1.00 
Males 2237 (54.1) 2210 (54.8) 456 1.26  (1.09 – 1.45) 1.37 (1.18 – 1.59) 
Age (yrs)      
35-55  1001 (24.5) 533 (13.1) 51 1.00 1.00 
56-63  964 (23.6) 647 (15.8) 138 2.72 (1.97 – 3.75) 2.66 (1.92 – 3.68) 
64-69  865 (21.2) 691 (16.9) 160 3.40 (2.48 – 4.67) 3.13 (2.27 – 4.32) 
70-76  781 (19.1) 939 (23.0) 205 4.61 (3.39 – 6.28) 4.09 (2.98 – 5.61) 
77-100  474 (11.6) 1275 (31.2) 217 5.95 (4.37 – 8.12) 4.86 (3.51 – 6.73) 
Smoking status      
Current 577 (14.1) 558 (13.7) 109 1.00 1.00 
Ex 1015 (24.9) 866 (21.2) 177 0.99 (0.78 – 1.26) 0.77 (0.60 – 0.98) 
Never 1637 (40.1) 1411 (34.5) 271 0.87 (0.69 – 1.09) 0.75 (0.60 - 0.94) 
Not known 856 (21.0) 1250 (30.6) 214 1.19 (0.94 – 1.51) 0.91 (0.72 – 1.16) 
Carstairs 
deprivation 
category 
     
1 (least 
deprived) 
224 (5.5) 206 (5.0) 46 1.00 1.00 
2 805 (19.7) 902 (22.1) 162 0.75 (0.56 – 1.01) 0.74 (0.55 – 0.99) 
3 1129 (27.6) 1171 (28.7) 223 0.80 0.61 – 1.07) 0.82 (0.62 – 1.09) 
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4 458 (11.2) 488 (12.0) 99 0.78 (0.56 – 1.08) 0.81 (0.58 – 1.12) 
5 521 (12.8) 457 (11.2) 77 0.66 (0.47 – 0.92) 0.69 (0.49 – 0.97) 
6 603 (14.8) 579 (14.2) 106 0.71 (0.52 – 0.98) 0.79 (0.58 – 1.09) 
7 (most 
deprived)  
345 (8.5) 282 (6.9) 58 0.72 (0.50 – 1.04) 0.83 (0.58 – 1.19) 
BMI      
Mean (sd) 30.7 (3.5) 28.6 (3.1) - 0.93 (0.91 – 0.95) 0.98 (0.96 – 1.00) 
HbA1c      
Mean (sd) 7.9 (1.0) 7.2 (1.2) - 0.77 (0.72 – 0.82) 0.91 (0.84 – 0.98)  
Use of insulin       
No use 3833 (93.8) 3512 (86.0) 696 1.00 1.00 
Use within 1 
year 
252 (6.2) 573 (14.0) 75 0.99 (0.85 – 1.15) 1.13 (0.97 – 1.33) 
Use of 
sulphonylureas 
     
No use 2196 (53.8) 1996 (73.3) 483 1.00 1.00 
Use within 3 
months  
1889 (46.2) 1089 (26.7) 288 1.00 (0.78 – 1.28) 1.12 (0.87 – 1.47) 
*
Adjusted for all covariates   
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Table 2: Unadjusted and adjusted hazard ratios for secondary outcomes; with adjusted hazard ratios (with 
95% CI) for incidence of cancer stratified by maximum prescribed dose and duration of follow-up (with 
comparators as the reference category).  
 No (%) with outcome  Unadjusted hazard 
ratio  (95% CI) 
Adjusted hazard ratio
*
 
(95% CI) 
Incidence of bowel 
cancer 
   
Comparators  76 (1.9) 1.00 1.00 
Users 40 (1.0) 0.41 (0.28 – 0.61) 0.60 (0.38 – 0.94) 
Incidence of lung cancer    
Comparators  58 (1.4) 1.00 1.00 
Users 35 (0.9) 0.49 (0.32 – 0.74) 0.70 (0.43 – 1.15) 
Incidence of female 
breast cancer 
   
Comparators  41 (2.2) 1.00 1.00 
Users 24 (1.3) 0.44 (0.26 – 0.73) 0.60 (0.32 – 1.10) 
Overall mortality     
Comparators 1422 (34.8) 1.00 1.00 
Users 609 (14.9) 0.32 (0.29 – 0.35) 0.42 (0.38- 0.47) 
Mortality from cancer     
Comparators  248 (6.1) 1.00 1.00 
Users 123 (3.0) 0.48 (0.39 – 0.60) 0.63 (0.49 - 0.81) 
Incidence of cancer 
Maximum prescribed 
dose during follow up 
(number of patients) 
Adjusted hazard ratios 
(95% CI)
* 
Adjusted hazard ratios 
(95% CI)
*
 
Adjusted hazard 
ratios (95% CI)
*
 
 < 2 years follow-up  2-4 years follow-up >4 years follow-up 
Low (1,017) 3.15 (1.92 – 5.18) 0.99 (0.44 – 2.25) 0.16 (0.06 – 0.44) 
Medium (2,090) 1.94 (1.20 – 3.13) 0.51 (0.31 – 0.82) 0.40 (0.27 – 0.60) 
High (978) 2.76 (0.56 – 13.45) 0.28 (0.12 – 0.70) 0.15 (0.09 – 0.25) 
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*
Adjusted for age, sex, smoking, deprivation, BMI, HbA1c, insulin use, sulphonylureas use  
 
FIGURE LEGENDS 
Fig 1: Flow chart showing how metformin users and comparators were selected for the study.  
Fig 2: Kaplan Meier plot with 95% confidence intervals showing time to cancer among 
metformin users and comparators. 
